Amgen
$233.779876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$233.77
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.36 (+0.15%) Today
$0.00 (0.00%) As of 8:00 PM EST after-hours
Why Robinhood?
You can buy or sell Amgen and other stocks, options, ETFs, and crypto commission-free!
About AMGN
Amgen Inc. Common Stock, also called Amgen, is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Read More Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Employees
21,500
Headquarters
Thousand Oaks, California
Founded
1980
Market Cap
138.69B
Price-Earnings Ratio
17.91
Dividend Yield
2.71
Average Volume
1.98M
High Today
$235.00
Low Today
$233.19
Open Price
$234.68
Volume
1.83M
52 Week High
$235.80
52 Week Low
$166.30
Collections
AMGN News
ReutersDec 6
UPDATE 1-FDA approves Amgen's biosimilar to J&J's rheumatoid arthritis drug
(Adds background, analyst comment) Dec 6 (Reuters) - The U.S. Food and Drug Administration on Friday approved Amgen Inc's biosimilar copy of Johnson & Johnson'
Analyst Ratings
46%
of 24 ratings
Buy
46%
Hold
54%
Sell
0%
AMGN Earnings
$3.22
$3.47
$3.72
$3.97
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
—
Actual
Expected Jan 28, After Hours
